Latest Articles

Publication Date
Epigenetic Compound Library Screen Identifies Ibrutinib as an Inhibitor of Ovarian Clear Cell Carcinoma Viability.

Ovarian clear cell carcinoma (OCCC) is an endometriosis-associated ovarian cancer subtype. Somatic mutations in OCCC are reported in ARID1A, PIK3CA, and the TERT promoter (TERTp), as well as less commonly …

Published: April 10, 2026, midnight
Woman with Stage 4 endometriosis and cancer diagnosis channels pain into repurposing jewelry - CTV News

Woman with Stage 4 endometriosis and cancer diagnosis channels pain into repurposing jewelry CTV News

Published: April 8, 2026, 6:01 p.m.
Exosome-Enriched Hub Gene Networks Identify Diagnostic Biomarkers and Repurposable Therapeutic Targets in Endometriosis.

Endometriosis is a heterogeneous chronic inflammatory disorder associated with substantial diagnostic delay and limited therapeutic options, highlighting the need of robust non-invasive biomarkers and actionable molecular targets to complement existing …

Published: March 11, 2026, midnight
Epigenetic Landscape of Female Infertility: An Integrated Bioinformatics Perspective on DNA Methylation, MicroRNAs, and Gene Regulatory Networks Across PCOS, Endometriosis, and Diminished Ovarian Reserve.

Female infertility diseases such as polycystic ovary syndrome (PCOS), endometriosis, diminished ovarian reserve (DOR), and recurrent implantation failure (RIF) have different clinical phenotypes. However, they might be epigenetically convergent, and …

Published: Feb. 12, 2026, midnight
Repurposing ramipril to mitigate EMT-like transition in endometriosis by PI3K/AKT/S6K1 signalling pathway: a study in endometriosis induced rats.

Endometriosis, an atypical benign disorder, may disrupt epithelial-mesenchymal transition (EMT) due to a dysregulated balance between matrix metalloproteinases (MMPs) and their inhibitors. Ramipril, an angiotensin converting enzyme (ACE) inhibitor, is …

Published: Jan. 28, 2026, midnight
An integrated multimodal approach to drug repurposing in endometriosis, using ROR1 as a target.

Endometriosis is a chronic, heterogeneous disease with limited non-hormonal treatment options. Drug repurposing provides an accelerated route to identify safe, tolerable, and potentially effective therapies for endometriosis. Receptor tyrosine kinase-like …

Published: Dec. 3, 2025, midnight
An integrated multimodal approach to drug repurposing in endometriosis, using ROR1 as a target - Frontiers

An integrated multimodal approach to drug repurposing in endometriosis, using ROR1 as a target Frontiers

Published: Nov. 17, 2025, 7:46 a.m.
Using systems biology and drug repositioning approaches to discover FDA-approved drugs candidates for endometriosis treatment.

Endometriosis is characterized by the presence of endometrial tissue outside the uterine cavity. The administration of drugs designated for this condition has significant adverse effects, such as signs of estrogen …

Published: Sept. 12, 2025, midnight
Multi-ancestry genome-wide association study of endometriosis and its clinical manifestations in ~1.4 million women: translating gene discovery into pathogenic mechanisms and therapeutic targets.

We conducted a multi-ancestry genome-wide association study of endometriosis and adenomyosis in almost 1.4 million women, including 105,869 cases, aiming to expand endometriosis loci discovery across ancestries, dissect symptom-specific effects, …

Published: Sept. 5, 2025, midnight
Neuroinflammation is responsible for pain in endometriosis - targeting the JAK-STAT pathway and mast cell activation.

Chronic pain is a defining feature of endometriosis and contributes significantly to the diminished quality of life observed in affected individuals. Despite advances in understanding disease pathology, current therapeutic strategies …

Published: Aug. 29, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!